Gingivitis
Conditions
Brief summary
Pilot case series with a split-mouth design to track subjects with known exposure (dental biofilm accumulation) over 21 days. Descriptive design, using single cell RNA sequencing as a digital biopsy to catalog and contrast inflamed versus non-inflamed tissues from within the same mouth and across patients. Specimens (human) will biobanked from the 'digital biopsy' site for future analysis, including: Gingival crevicular fluid, oral epithelial stem/progenitor cells, and plaque samples, for 'omics analyses including metabolomics, microbiomic, and genomic data.
Detailed description
Purpose is to conduct the first study of human gingiva in health and after biofilm-induced inflammation in the gingiva using scRNAseq. The pilot will involve induction of experimental gingivitis in all participants. Participants include recruitment of 6 participants. Following consenting, screening, and enrollment, a customized acrylic stent will be used only on the selected sextant/teeth specified in the protocol, and only during tooth brushing to prevent oral hygiene in selected sextant/teeth. After the completion of the 3-week gingivitis induction phase, participants will enter a 2 week resolution phase. In the resolution phase, participants will reinstate full mouth oral hygiene, with the exception of flossing. Oral prophylaxis will be performed to regain health. During the 3 week gingivitis induction phase, participants will be required to return to the clinic every 7 days for safety checks. Study Procedures (methods): Medical history, demographics (height/weight), urine based pregnancy test, vital signs (to include blood pressures, and pulse), standard dental clinical measures (to include plaque index, gingival index, bleeding on probing, and clinical attachment level), alginate impressions taken for fabrication of an acrylic stent (mouth guard), 2 gingival biopsies, 4 subgingival (below the gum line) plaque samples, 4 Gingival Crevicular Fluid (naturally occurring fluid between the gum and teeth) samples, and adult prophylaxis
Interventions
PROCEDUREStent-Induced Biofilm Overgrowth
Customized acrylic dental (sextant) stent will be used during brushing for 21 days to influence reversible gingival tissue inflammation.
Sponsors
Sunstar, Inc.
University of North Carolina, Chapel Hill
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 30 Years
Healthy volunteers
Yes
Inclusion criteria
* Adult males or females between the age of 18 and 30 years. * Non-diabetic and no history of smoking within the last 5 years. * Have read, understood and signed an informed consent form. * Must be able and willing to follow study procedures and instructions. * Must have at least 3 natural adjacent teeth in both maxillary (top) posterior sextants that will be selected for baseline gingival biopsy and SIBO gingival biopsy. * Must be in good general health, as evidenced by medical hx (exclusion conditions defined under subject
Exclusion criteria
below). * Females of childbearing capacity must be willing to have pregnancy test to confirm they are not pregnant.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Genes Expressed In Mesenchymal Cell Subtypes at Day 1 | Day 1 | Gene expression will be ranked by highest to lowest and a list of the top 100 genes in mesenchymal cell subtypes in health will be produced. |
| Percent Composition of Human Gingival Tissue at Day 1 | Day 1 | Percentage of the human gingival biopsies that are epithelial, immune, or mesenchymal cells in health. |
| Percent Composition of Human Gingival Tissue at Day 21 | Day 21 | Percentage of the human gingival biopsies that are epithelial, immune, or mesenchymal cells during inflammation. |
| Percent Composition of Human Gingival Epithelial Cells at Day 1 | Day 1 | Percentage of the human gingival epithelial cell subtypes that are present (i.e. keratinocytes, Langerhans cells, etc.) in health. |
| Percent Composition of Human Gingival Epithelial Cells at Day 21 | Day 21 | Percentage of the human gingival epithelial cell subtypes that are present (i.e. keratinocytes, Langerhans cells, etc.) during inflammation. |
| Percent Composition of Human Gingival Immune Cells at Day 1 | Day 1 | Percentage of the human immune cell subtypes that are present (i.e. CD4, CD8, etc.) in health. |
| Percent Composition of Human Gingival Immune Cells at Day 21 | Day 21 | Percentage of the human immune cell subtypes that are present (i.e. CD4, CD8, etc.) during inflammation. |
| Percent Composition of Human Gingival Mesenchymal Cells at Day 1 | Day 1 | Percentage of the human mesenchymal cell subtypes that are present (i.e. stromal endothelial, etc.) in health. |
| Percent Composition of Human Gingival Mesenchymal Cells at Day 21 | Day 21 | Percentage of the human mesenchymal cell subtypes that are present (i.e. stromal endothelial, etc.) in health. |
| Genes Expressed In Epithelial Cells at Day 1 | Day 1 | Gene expression will be ranked by highest to lowest and a list of the top 100 genes in epithelial cells in health will be produced. |
| Genes Expressed In Epithelial Cells at Day 21 | Day 21 | Gene expression will be ranked by highest to lowest and a list of the top 100 genes in epithelial cells during inflammation will be produced. |
| Genes Expressed In Immune Cells at Day 1 | Day 1 | Gene expression will be ranked by highest to lowest and a list of the top 100 genes in immune cells in health will be produced. |
| Genes Expressed In Immune Cells at Day 21 | Day 21 | Gene expression will be ranked by highest to lowest and a list of the top 100 genes in immune cells during inflammation will be produced. |
| Genes Expressed In Mesenchymal Cells at Day 1 | Day 1 | Gene expression will be ranked by highest to lowest and a list of the top 100 genes in mesenchymal cells in health will be produced. |
| Genes Expressed In Mesenchymal Cells at Day 21 | Day 21 | Gene expression will be ranked by highest to lowest and a list of the top 100 genes in mesenchymal cells during inflammation will be produced. |
| Genes Expressed In Epithelial Cell Subtypes at Day 1 | Day 1 | Gene expression will be ranked by highest to lowest and a list of the top 100 genes in epithelial cell subtypes in health will be produced. |
| Genes Expressed In Epithelial Cell Subtypes at Day 21 | Day 21 | Gene expression will be ranked by highest to lowest and a list of the top 100 genes in epithelial cell subtypes during inflammation will be produced. |
| Genes Expressed In Immune Cell Subtypes at Day 1 | Day 1 | Gene expression will be ranked by highest to lowest and a list of the top 100 genes in immune cell subtypes in health will be produced. |
| Genes Expressed In Immune Cell Subtypes at Day 21 | Day 21 | Gene expression will be ranked by highest to lowest and a list of the top 100 genes in immune cell subtypes during inflammation will be produced. |
| Genes Expressed In Mesenchymal Cell Subtypes at Day 21 | Day 21 | Gene expression will be ranked by highest to lowest and a list of the top 100 genes in mesenchymal cell subtypes during inflammation will be produced. |
Countries
United States
Outcome results
None listed